Key result
Tailor HFpEF management to individual comorbidities as conventional HFrEF therapies show no mortality benefit.
Why the study?
Heart failure with preserved ejection fraction is highly heterogenous, no current management algorithms exist, and conventional therapies used in heart failure with reduced ejection fraction have yet to show a mortality benefit.
Management of HFpEF currently relies on tailoring treatment to individual comorbidities such as hypertension, coronary artery disease, and atrial fibrillation.
Tailors HFpEF care to comorbidities pending specific therapies; leaves open trials demonstrating mortality benefit.
Heart failure with preserved ejection fraction is a highly heterogenous disease. There is emerging evidence that treatment should be tailored to the individual’s associated comorbidities No current algorithms exist for the management of heart failure with preserved ejection fraction. Conventional therapies used in heart failure with reduced ejection fraction are yet to show a mortality benefit Key treatment objectives include control of hypertension and fluid balance Common comorbidities include coronary artery disease, atrial fibrillation, obesity, diabetes, renal impairment and pulmonary hypertension. These comorbidities should be considered in all patients and treatment optimised
No takes yet. Share an insight, caveat, or question.
Gard et al. (2020) conducted a review in Heart failure with preserved ejection fraction. Management of heart failure with preserved ejection fraction should be tailored to individual comorbidities, as conventional therapies for reduced ejection fraction have not shown a mortality benefit.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: